1-10 of 10
Bruce A. Feinberg
Close
Sort by
Journal Articles

The Determination Trial Impact on Upfront (vs Delayed) Autologous Stem Cell Transplantation for Transplant-Eligible Newly Diagnosed Multiple Myeloma

Brooke Dulka, Robert N. Bone, Yolaine Jeune-Smith, Muhamed Baljevic, Bruce A. Feinberg
Journal: Blood
Blood (2022) 140 (Supplement 1): 10958–10959.
https://doi.org/10.1182/blood-2022-166490
Published: 2022
Journal Articles

Provider Perceptions of Shine and Ibrutinib, Bendamustine, and Rituximab in the First-Line Setting

Samuel C. Baird, Robert N. Bone, Yolaine Jeune-Smith, Bruce A. Feinberg, Muhamed Baljevic
Journal: Blood
Blood (2022) 140 (Supplement 1): 13234–13235.
https://doi.org/10.1182/blood-2022-166976
Published: 2022
Journal Articles

CAR T Therapy Referral for Diffuse Large B Cell Lymphoma (DLBCL) By U.S. Community Hematology/Oncology (cH/O) Practices: Perceptions and Patterns

David L Porter, Andrew J Klink, Alexandrina Balanean, Lindsay McAllister, Bruce A. Feinberg
Journal: Blood
Blood (2021) 138 (Supplement 1): 4977.
https://doi.org/10.1182/blood-2021-151807
Published: 2021
Journal Articles

Barriers to Referral for Chimeric Antigen Receptor T Cell (CAR-T) Therapies Among U.S. Community Hematologists/Oncologists (cH/O)

Ajeet Gajra, Yolaine Jeune-Smith, Bruce A. Feinberg
Journal: Blood
Blood (2021) 138 (Supplement 1): 4010.
https://doi.org/10.1182/blood-2021-151789
Published: 2021
Journal Articles

Clinical Outcomes at 3 and 6 Months of Fedratinib Therapy Following Prior Ruxolitinib Failure: Real-World Assessment of Spleen, Symptoms, and Hematologic Response

John Mascarenhas, Aaron T. Gerds, Arianna Kee, Jonathan K. Kish, Pranav Abraham, Alexandrina Balanean, Jose Alberto Nadal, Djibril Liassou, Bruce A. Feinberg, Ali McBride, Claire N. Harrison
Journal: Blood
Blood (2021) 138 (Supplement 1): 1980.
https://doi.org/10.1182/blood-2021-145573
Published: 2021
Journal Articles

U.S-Based Community Oncologists/Hematologists' Perceptions Regarding Future Use of Gene Therapies for Patients with Hematological Disorders

Ajeet Gajra, Stephanie Fortier, Yolaine Jeune-Smith, Bruce A. Feinberg
Journal: Blood
Blood (2021) 138 (Supplement 1): 2986.
https://doi.org/10.1182/blood-2021-148165
Published: 2021
Journal Articles

Real-World Utilization of Fedratinib for Myelofibrosis Post-Ruxolitinib: Patient Characteristics, Treatment Patterns, and Characterization of Ruxolitinib Failure

Claire N. Harrison, John Mascarenhas, Pranav Abraham, Arianna Kee, Jose Alberto Nadal, Alexandrina Balanean, Ali McBride, Jonathan K. Kish, Djibril Liassou, Bruce A. Feinberg, Aaron T. Gerds
Journal: Blood
Blood (2021) 138 (Supplement 1): 3059.
https://doi.org/10.1182/blood-2021-145569
Published: 2021
Journal Articles

Real-World Analysis of Adverse Events Associated with CAR T-Cell Therapy Among Adults Age ≥65 Years

Marjorie E Zettler, PhD MPH, Bruce A Feinberg, DO, Eli G Phillips Jr., PharmD, JD, Andrew J Klink, PhD MPH, Sonam Mehta, Ajeet Gajra, MD FACP
Journal: Blood
Blood (2019) 134 (Supplement_1): 1951.
https://doi.org/10.1182/blood-2019-127372
Published: 2019
Journal Articles

Perceptions of Community Hematologists/Oncologists on Barriers to Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Diffuse Large B-Cell Lymphoma

Ajeet Gajra, MD FACP, Richard Sweat, PhD, Yolaine Jeune-Smith, PhD, Jonathan K. Kish, PhD MPH, Bruce A Feinberg, DO
Journal: Blood
Blood (2019) 134 (Supplement_1): 2198.
https://doi.org/10.1182/blood-2019-127741
Published: 2019
Journal Articles

Potential of 2018 ASH CLL Data to Alter Standard of Care for Initial CLL Treatment

Bruce A Feinberg, DO, Richard Sweat, PhD, Yolaine Jeune-Smith, PhD, Ajeet Gajra, MD FACP
Journal: Blood
Blood (2019) 134 (Supplement_1): 5816.
https://doi.org/10.1182/blood-2019-129029
Published: 2019